^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1

    Published date:
    04/06/2023
    Excerpt:
    For patients with non-SCC, PD-L1 TPS 0%-49% and PS 0-1, clinicians may offer durvalumab and tremelimumab plus platinum-based chemotherapy…
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.23.00282
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    PD-L1≥1-49% First-Line Therapy...The following regimens added as Other Recommended...Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel (category 2B)...Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + pemetrexed (nonsquamous) (category 2B).
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

    Excerpt:
    ......
    Trial ID:
    NCT04499053